These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
120 related articles for article (PubMed ID: 252780)
1. [Parkinson's disease]. de Saxce H Rev Infirm; 1979 Jan; 29(1):50-7. PubMed ID: 252780 [No Abstract] [Full Text] [Related]
2. [Updates in practical neurology--I. The principles of modern levodopa therapy in Parkinson's disease]. Klivényi P; Vécsei L Ideggyogy Sz; 2007 Jan; 60(1-2):61-4. PubMed ID: 17432097 [TBL] [Abstract][Full Text] [Related]
3. Levodopa for the treatment of Parkinson's disease. Lewitt PA N Engl J Med; 2008 Dec; 359(23):2468-76. PubMed ID: 19052127 [No Abstract] [Full Text] [Related]
4. Reevaluation of levodopa therapy for the treatment of advanced Parkinson's disease. Yokochi M Parkinsonism Relat Disord; 2009 Jan; 15 Suppl 1():S25-30. PubMed ID: 19131038 [TBL] [Abstract][Full Text] [Related]
5. The variability of levodopa response in Parkinson's disease: is sensitization reversible? Jabre MG; Bejjani BP Mov Disord; 2008 Apr; 23(6):924; author reply 925. PubMed ID: 18163452 [No Abstract] [Full Text] [Related]
6. The neurochemistry of therapeutics: levodopa pharmacodynamics in Parkinson's disease. Frey KA Ann Neurol; 2001 Mar; 49(3):285-7. PubMed ID: 11261500 [No Abstract] [Full Text] [Related]
8. [Drug therapy in Parkinson's disease]. van Hilten JJ; Roos RA Ned Tijdschr Geneeskd; 1999 Jan; 143(5):234-40. PubMed ID: 10086151 [TBL] [Abstract][Full Text] [Related]
9. Levodopa for Parkinson's disease. Gérard JM; Elosegi JA N Engl J Med; 2009 Feb; 360(9):936; author reply 936. PubMed ID: 19256032 [No Abstract] [Full Text] [Related]
10. Development of new pharmacological approaches in Parkinson's disease. Carlsson A Adv Neurol; 1987; 45():513-8. PubMed ID: 3493631 [No Abstract] [Full Text] [Related]
11. Synaptic plasticity, dopamine and Parkinson's disease: one step ahead. Calabresi P; Mercuri NB; Di Filippo M Brain; 2009 Feb; 132(Pt 2):285-7. PubMed ID: 19168452 [No Abstract] [Full Text] [Related]
12. Neuroprotective and neurotoxic roles of levodopa (L-DOPA) in neurodegenerative disorders relating to Parkinson's disease. Kostrzewa RM; Kostrzewa JP; Brus R Amino Acids; 2002; 23(1-3):57-63. PubMed ID: 12373519 [TBL] [Abstract][Full Text] [Related]
13. Dopaminergic modulation of cognitive function-implications for L-DOPA treatment in Parkinson's disease. Cools R Neurosci Biobehav Rev; 2006; 30(1):1-23. PubMed ID: 15935475 [TBL] [Abstract][Full Text] [Related]
14. The 'magic' of L-dopa: why is it the gold standard Parkinson's disease therapy? Mercuri NB; Bernardi G Trends Pharmacol Sci; 2005 Jul; 26(7):341-4. PubMed ID: 15936832 [TBL] [Abstract][Full Text] [Related]
15. Treatment options for early Parkinson's disease. Stacy M; Brownlee HJ Am Fam Physician; 1996 Mar; 53(4):1281-7. PubMed ID: 8629572 [TBL] [Abstract][Full Text] [Related]
16. Drug management of Parkinson's disease. Kishore A; Snow BJ Can Fam Physician; 1996 May; 42():946-52. PubMed ID: 8688697 [TBL] [Abstract][Full Text] [Related]
17. [Controversial issues concerning the initial treatment of Parkinson's disease: L-Dopa or dopaminergic agonists?]. Defer GL Rev Neurol (Paris); 1999 Jan; 155(1):43-5. PubMed ID: 10093847 [No Abstract] [Full Text] [Related]